Richard L Schilsky

List of Publications by Year in Descending Order

161 papers	7,857 citations	38 h-index	87 g-index
172 ext. papers	9,703 ext. citations	5.8 avg, IF	5.83 L-index

#	Paper	IF	Citations
161	Use of Biosimilar Medications in Oncology.. *JCO Oncology Practice*, **2022**, OP2100771	2.3	1
160	Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2022**, 40, 106-106	2.2	1
159	Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2022**, 40, 107-107	2.2	2
158	Patient Experiences, Trust, and Preferences for Health Data Sharing. *JCO Oncology Practice*, **2021**, OP2100491	2.3	0
157	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. *JCO Oncology Practice*, **2021**, OP2100394	2.3	4
156	Governance of a Learning Health Care System for Oncology: Patient Recommendations. *JCO Oncology Practice*, **2021**, 17, e479-e489	2.3	2
155	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. *Journal of Clinical Oncology*, **2021**, 39, 1165-1184	2.2	16
154	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. *Npj Precision Oncology*, **2021**, 5, 33	9.8	2
153	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2021**, 39, 5508-5508	2.2	4
152	Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2021**, 39, 6043-6043	2.2	1
151	Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2021**, 39, 11565-11565	2.2	2
150	Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.. *Journal of Clinical Oncology*, **2021**, 39, 6509-6509	2.2	
149	What can heart failure trialists learn from oncology trialists?. *European Heart Journal*, **2021**, 42, 2373-2383	35	4
148	Strategic development of precision cancer medicine in the United States. *Molecular Oncology*, **2021**, 15, 1747-1749	7.9	1
147	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. *Journal of Clinical Oncology*, **2021**, 39, 155-169	2.2	38
146	The International Collaboration for Cancer Classification and Research. *International Journal of Cancer*, **2021**, 148, 560-571	7.5	9
145	Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. *JCO Oncology Practice*, **2021**, 17, 41-51	2.3	1

144	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. *Clinical Cancer Research*, **2021**, 27, 2408-2415	12.9	6
143	Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. *Clinical Cancer Research*, **2021**, 27, 2394-2399	12.9	11
142	Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Recommendations. *Clinical Cancer Research*, **2021**, 27, 2430-2434	12.9	9
141	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *Journal of Clinical Oncology*, **2021**, 39, 2443-2451	2.2	27
140	The National Clinical Trials Network and the cooperative groups: The road not taken. *Cancer*, **2020**, 126, 5008-5013	6.4	1
139	Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology. *JCO Oncology Practice*, **2020**, 16, e977-e990	2.3	3
138	Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. *JCO Oncology Practice*, **2020**, 16, 417-421	2.3	90
137	Status Update on Data Required to Build a Learning Health System. *Journal of Clinical Oncology*, **2020**, 38, 1602-1607	2.2	11
136	Reply to M. Hutton-Potts and A.M. Joshua. *JCO Oncology Practice*, **2020**, 16, 285-286	2.3	
135	Palbociclib in Patients With Non-Small-Cell Lung Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.. *JCO Precision Oncology*, **2020**, 4, 757-766	3.6	15
134	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2020**, 38, 1081	2.2	48
133	Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2020**, 38, 4637-4637	2.2	6
132	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.. *Journal of Clinical Oncology*, **2020**, 38, 122-122	2.2	7
131	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.. *Journal of Clinical Oncology*, **2020**, 38, 132-132	2.2	18
130	Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. *Journal of Clinical Oncology*, **2020**, 38, 133-133	2.2	12
129	Biosimilar usage in practices within the ASCO PracticeNET learning network.. *Journal of Clinical Oncology*, **2020**, 38, 77-77	2.2	1
128	Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2020**, 38, 5567-5567	2.2	2
127	Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. *Oncologist*, **2020**, 25, e405-e411	5.7	1

126	Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. *Journal of Clinical Oncology*, **2020**, 38, 480-487	2.2	3
125	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. *JCO Global Oncology*, **2020**, 6, 1461-1471	3.7	26
124	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *Targeted Oncology*, **2020**, 15, 743-750	5	9
123	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. *JAMA Network Open*, **2020**, 3, e2014661	10.4	1
122	Closing the Rural Cancer Care Gap: Three Institutional Approaches. *JCO Oncology Practice*, **2020**, 16, 422-430	2.5	37
121	Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *Targeted Oncology*, **2020**, 15, 733-741	5	10
120	Progress in Cancer Research, Prevention, and Care. *New England Journal of Medicine*, **2020**, 383, 897-900	59.2	18
119	Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. *Journal of Clinical Oncology*, **2019**, 37, 3203-3211	2.2	9
118	Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. *Journal of Clinical Oncology*, **2019**, 37, 1690-1694	2.2	9
117	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nature Medicine*, **2019**, 25, 751-758	50.5	205
116	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. *Journal of Clinical Oncology*, **2019**, 37, 72-80	2.2	12
115	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. *Journal of Clinical Oncology*, **2019**, 37, 336-349	2.2	66
114	Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. *Journal of Oncology Practice*, **2019**, 15, 575-583	3.1	5
113	Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. *Oncologist*, **2019**, 24, 1287-1290	5.7	8
112	Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. *Journal of Clinical Oncology*, **2019**, 37, 1014-1014	2.2	23
111	Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. *Journal of Clinical Oncology*, **2019**, 37, 9041-9041	2.2	6
110	Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. *Journal of Clinical Oncology*, **2019**, 37, LBA108-LBA108	2.2	10
109	Hypertension and use of bevacizumab among patients treated in community settings.. *Journal of Clinical Oncology*, **2019**, 37, e18279-e18279	2.2	

108	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. *Journal of Clinical Oncology*, **2019**, 37, 6531-6531	2.2	0
107	Challenges and approaches to implementing master/basket trials in oncology. *Blood Advances*, **2019**, 3, 2237-2243	7.8	8
106	Palbociclib in Patients With Pancreatic and Biliary Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.. *JCO Precision Oncology*, **2019**, 3, 1-8	3.6	14
105	Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.. *JCO Precision Oncology*, **2019**, 3, 1-10	3.6	2
104	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 1242-1253	5	72
103	Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?. *JAMA Oncology*, **2018**, 4, 333-334	13.4	9
102	The evidence framework for precision cancer medicine. *Nature Reviews Clinical Oncology*, **2018**, 15, 183-192	19.4	89
101	Hans Christian Andersen and the Value of New Cancer Treatments. *Journal of the National Cancer Institute*, **2018**, 110, 441-442	9.7	4
100	Access versus evidence: The regulatorsRdilemma. *Clinical Trials*, **2018**, 15, 240-242	2.2	3
99	Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. *Journal of Clinical Oncology*, **2018**, 36, 2532-2532	2.2	3
98	Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).. *Journal of Clinical Oncology*, **2018**, 36, 638-638	2.2	3
97	Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists.. *Journal of Clinical Oncology*, **2018**, 36, 6529-6529	2.2	
96	Reply to S.D. Lucio. *Journal of Clinical Oncology*, **2018**, 36, 2127	2.2	
95	A New Look at the State of Cancer Care in America. *Journal of Oncology Practice*, **2018**, 14, 397-399	3.1	2
94	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2018**, 36, 1020-1044	2.2	83
93	American Society of Clinical Oncology Statement: Biosimilars in Oncology. *Journal of Clinical Oncology*, **2018**, 36, 1260-1265	2.2	65
92	Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *JCO Precision Oncology*, **2018**, 2018,	3.6	53
91	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. *Journal of Clinical Oncology*, **2018**, 36, 617-623	2.2	16

90	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *Journal of Clinical Oncology*, **2018**, 36, 1631-1641	2.2	448
89	The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. *Journal of Oncology Practice*, **2018**, 14, e412-e420	3.1	61
88	Accelerating anticancer drug development - opportunities and trade-offs. *Nature Reviews Clinical Oncology*, **2018**, 15, 777-786	19.4	32
87	Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement **2018**, 6, 108		11
86	Rationale, Opportunities, and Reality of Biosimilar Medications. *New England Journal of Medicine*, **2018**, 378, 2036-2044	59.2	41
85	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. *European Journal of Cancer*, **2018**, 100, 35-45	7.5	20
84	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2017**, 35, 1341-1367	2.2	75
83	Reply to L. Casadaban et al. *Journal of Clinical Oncology*, **2017**, 35, 1373-1374	2.2	
82	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2392-2401	27.4	434
81	Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. *Journal of Clinical Oncology*, **2017**, 35, 1134	2.2	
80	Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. *Journal of Clinical Oncology*, **2017**, 35, 3737-3744	2.2	225
79	Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. *Cell*, **2017**, 171, 982-986	56.2	12
78	Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge. *Journal of the American College of Surgeons*, **2017**, 224, 1-7	4.4	27
77	Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.. *Journal of Clinical Oncology*, **2017**, 35, e18290-e18290	2.2	1
76	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *Journal of Clinical Oncology*, **2016**, 34, 179-85	2.2	165
75	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). *Journal of Clinical Oncology*, **2016**, 34, 3047-53	2.2	33
74	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3872-3879	2.2	16
73	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. *Journal of Clinical Oncology*, **2016**, 34, 3992-3999	2.2	60

72	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. *Journal of Clinical Oncology*, **2016**, 34, 2925-34	2.2	384
71	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2016**, 34, 987-1011	2.2	114
70	Response. *Journal of the National Cancer Institute*, **2016**, 108, djw001	9.7	
69	Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials.. *Journal of Clinical Oncology*, **2016**, 34, 11520-11520	2.2	3
68	Impact of primary (1□) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. *Journal of Clinical Oncology*, **2016**, 34, 3504-3504	2.2	193
67	Highlights from the 2016 WIN Symposium, 27-29 June 2016, Paris: personalised therapy beyond next-generation sequencing. *Ecancermedicalscience*, **2016**, 10, 669	2.7	1
66	Creating a Learning Health Care System in Oncology **2016**, 3-21		2
65	Circadian variation in plasma 5-fluorouracil concentrations during a 24□hour constant-rate infusion. *BMC Cancer*, **2015**, 15, 69	4.8	13
64	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. *Journal of Clinical Oncology*, **2015**, 33, 2563-77	2.2	599
63	Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	19
62	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	106
61	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 3817-25	2.2	286
60	Modernizing Eligibility Criteria for Molecularly Driven Trials. *Journal of Clinical Oncology*, **2015**, 33, 2815-20	2.2	59
59	Highlights from the 2015 WIN Symposium: novel targets, innovative agents, and advanced technologies-a WINning strategy?. *Ecancermedicalscience*, **2015**, 9, 564	2.7	2
58	Using Big Data to Track Trends in Medical Practice. *Journal of Oncology Practice*, **2015**, 11, 69-70	3.1	
57	Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 484-9	4	10
56	Moving from evaluation to value in cancer care. *Clinical Cancer Research*, **2015**, 21, 947-9	12.9	4
55	Integrating biomarkers in colorectal cancer trials in the West and China. *Nature Reviews Clinical Oncology*, **2015**, 12, 553-60	19.4	9

54	Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). *Journal of the National Cancer Institute*, **2015**, 107, 336	9.7	23
53	Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2015**, 33, 786-809	2.2	91
52	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. *Oncotarget*, **2015**, 6, 14139-52	3.3	19
51	Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials.. *Journal of Clinical Oncology*, **2015**, 33, 11097-11097	2.2	
50	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. *Journal of Clinical Oncology*, **2015**, 33, 3585-3585	2.2	
49	Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2015**, 33, 7524-7524	2.2	
48	Recommendations for management of patients with neuroendocrine liver metastases. *Lancet Oncology, The*, **2014**, 15, e8-21	21.7	315
47	Wither the cooperative groups?. *Journal of Clinical Oncology*, **2014**, 32, 251-4	2.2	6
46	Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. *Journal of Clinical Oncology*, **2014**, 32, 1521-30	2.2	33
45	American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *Journal of Clinical Oncology*, **2014**, 32, 1277-80	2.2	273
44	Precision cancer medicine: the future is now, only better. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2014**, 61-9	7.1	30
43	Reply to F.E. Vera-Badillo et al. *Journal of Clinical Oncology*, **2014**, 32, 3198	2.2	
42	Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. *Journal of Clinical Oncology*, **2014**, 32, 2373-9	2.2	79
41	Reply to L.k. Griffeth et al and J.E. Battley et al. *Journal of Clinical Oncology*, **2014**, 32, 2812-3	2.2	
40	Implementing personalized cancer care. *Nature Reviews Clinical Oncology*, **2014**, 11, 432-8	19.4	63
39	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum	2.2	60
38	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. *Journal of Clinical Oncology*, **2014**, 32, LBA3-LBA3	2.2	131
37	Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.. *Journal of Clinical Oncology*, **2014**, 32, 455-455	2.2	3

36	Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.. *Journal of Clinical Oncology*, **2014**, 32, 11047-11047	2.2	
35	ASCO's initiative to define value in cancer care. *American Journal of Managed Care*, **2014**, 20, E1	2.1	
34	Publicly funded clinical trials and the future of cancer care. *Oncologist*, **2013**, 18, 232-8	5.7	16
33	Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. *Journal of Clinical Oncology*, **2013**, 31, 1775-81	2.2	127
32	Developing a virtual collaborative to facilitate palliative care and quality improvement learning in oncology.. *Journal of Clinical Oncology*, **2013**, 31, 252-252	2.2	1
31	Highlights from the 2013 WIN Symposium: personalised cancer therapy from innovation to implementation. *Ecancermedicalscience*, **2013**, 7, 344	2.7	
30	A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype.. *Journal of Clinical Oncology*, **2013**, 31, 2570-2570	2.2	
29	Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.. *Journal of Clinical Oncology*, **2013**, 31, 237-237	2.2	
28	Randomized controlled trials and comparative effectiveness research. *Journal of Clinical Oncology*, **2012**, 30, 4194-201	2.2	26
27	Development and use of integral assays in clinical trials. *Clinical Cancer Research*, **2012**, 18, 1540-6	12.9	34
26	Scarcity of vital oncology drugs: finding long-term solutions. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 597-9	0.6	
25	Targeted therapy for cancer: asking the right questions. *Oncology*, **2012**, 26, 947-9	1.8	
24	Advanced clinical trials for China. *Chinese Clinical Oncology*, **2012**, 1, 3	2.3	
23	Update in hematology and oncology: evidence published in 2010. *Annals of Internal Medicine*, **2011**, 154, 487-94	8	
22	Accrual to cancer clinical trials in the era of molecular medicine. *Science Translational Medicine*, **2011**, 3, 75cm9	17.5	16
21	Drug approval challenges in the age of personalized cancer treatment. *Personalized Medicine*, **2011**, 8, 633-640	2.2	4
20	Commentary: tackling the challenges of developing targeted therapies for cancer. *Oncologist*, **2010**, 15, 484-7	5.7	14
19	Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. *Journal of Clinical Oncology*, **2009**, 27, 3725-30	2.2	30

18	How not to treat cancer. *Lancet Oncology, The*, **2008**, 9, 504-5	21.7	3
17	Phase I and II clinical trial design for targeted agents. *Targeted Oncology*, **2006**, 1, 220-227	5	2
16	A concise history of the cancer and leukemia group B. *Clinical Cancer Research*, **2006**, 12, 3553s-5s	12.9	19
15	Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. *Journal of Clinical Oncology*, **2006**, 24, 4553-7	2.2	58
14	Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. *Journal of Clinical Oncology*, **2005**, 23, 8181-8200	2.2	87
13	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *Journal of Clinical Oncology*, **2003**, 21, 1431-9	2.2	1245
12	Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. *Journal of Clinical Oncology*, **2002**, 20, 582-7	2.2	45
11	Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. *Investigational New Drugs*, **1999**, 17, 97-101	4.3	23
10	Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). *Cancer Chemotherapy and Pharmacology*, **1998**, 42, 84-7	3.5	22
9	Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. *Stem Cells*, **1996**, 14, 29-32	5.8	11
8	Methotrexate: An Effective Agent for Treating Cancer and Building Careers. The Polyglutamate Era. *Oncologist*, **1996**, 1, 244-247	5.7	4
7	Prognostic factors for survival in patients treated in phase I clinical trials. *Cancer*, **1994**, 74, 1965-73	6.4	52
6	Sequential therapy with dacarbazine and carmustine: a phase I study. *Cancer Chemotherapy and Pharmacology*, **1994**, 34, 509-14	3.5	8
5	Modulation of vinblastine resistance with cyclosporine: a phase I study. *Clinical Pharmacology and Therapeutics*, **1993**, 54, 421-9	6.1	37
4	Clinical cardiotoxicity of esorubicin (4Rdeoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. *Investigational New Drugs*, **1990**, 8, 221-6	4.3	4
3	Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. *Journal of the National Cancer Institute*, **1990**, 82, 1411-5	9.7	37
2	A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. *Cancer*, **1989**, 63, 30-6	6.4	35
1	Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. *Otolaryngology - Head and Neck Surgery*, **1988**, 98, 295-8	5.5	9